See more : R&B Food Supply Public Company Limited (RBF.BK) Income Statement Analysis – Financial Results
Complete financial analysis of Indivior PLC (INDV) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Indivior PLC, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- H2O Innovation Inc. (HEOFF) Income Statement Analysis – Financial Results
- CIFI Holdings (Group) Co. Ltd. (0884.HK) Income Statement Analysis – Financial Results
- Ingenta plc (ING.L) Income Statement Analysis – Financial Results
- QuantGate Systems Inc. (QGSI) Income Statement Analysis – Financial Results
- Kingworld Medicines Group Limited (1110.HK) Income Statement Analysis – Financial Results
Indivior PLC (INDV)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.indivior.com
About Indivior PLC
Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1.09B | 884.63M | 777.48M | 689.68M | 815.16M | 959.92M | 1.15B | 968.89M |
| Cost of Revenue | 186.00M | 168.87M | 137.61M | 116.19M | 165.11M | 134.68M | 122.90M | 110.81M |
| Gross Profit | 907.00M | 715.75M | 639.87M | 573.49M | 650.05M | 825.25M | 1.03B | 858.08M |
| Gross Profit Ratio | 82.98% | 80.91% | 82.30% | 83.15% | 79.75% | 85.97% | 89.30% | 88.56% |
| Research & Development | 106.00M | 70.69M | 51.11M | 42.64M | 55.04M | 63.99M | 93.49M | 108.98M |
| General & Administrative | 575.00M | 545.00M | 239.00M | 447.00M | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 236.00M | 218.00M | 192.00M | 202.00M | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 811.00M | 439.86M | 404.96M | 437.05M | 385.25M | 444.14M | 508.40M | 411.18M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 911.00M | 510.55M | 456.07M | 479.69M | 440.29M | 508.14M | 601.89M | 520.16M |
| Cost & Expenses | 1.10B | 679.43M | 593.68M | 595.88M | 605.40M | 642.82M | 724.79M | 630.97M |
| Interest Income | 43.00M | 18.00M | 1.00M | 7.00M | 24.92M | 16.24M | 7.35M | 0.00 |
| Interest Expense | 37.00M | 29.00M | 26.00M | 24.00M | 20.77M | 29.61M | 51.47M | 51.00M |
| Depreciation & Amortization | 28.00M | 20.62M | 21.62M | 27.72M | 29.08M | 15.28M | 13.66M | 12.82M |
| EBITDA | 68.61M | -44.18M | 233.93M | -128.98M | 214.00M | 310.42M | 436.97M | 149.27M |
| EBITDA Ratio | 6.28% | 25.53% | 26.42% | 17.62% | 29.30% | 34.63% | 38.06% | 36.20% |
| Operating Income | -4.00M | 205.20M | 183.80M | 93.81M | 209.76M | 317.11M | 423.32M | 337.92M |
| Operating Income Ratio | -0.37% | 23.20% | 23.64% | 13.60% | 25.73% | 33.03% | 36.87% | 34.88% |
| Total Other Income/Expenses | 5.00M | -10.00M | -23.00M | -17.00M | -22.85M | -14.00M | -56.00M | -51.00M |
| Income Before Tax | 1.00M | -93.27M | 186.75M | -184.41M | 186.92M | 265.53M | 143.91M | 89.75M |
| Income Before Tax Ratio | 0.09% | -10.54% | 24.02% | -26.74% | 22.93% | 27.66% | 12.53% | 9.26% |
| Income Tax Expense | -1.00M | -41.24M | -14.74M | -26.65M | 47.77M | 2.87M | 82.98M | 57.69M |
| Net Income | 2.00M | -52.04M | 205.00M | -157.76M | 139.15M | 262.67M | 60.92M | 32.05M |
| Net Income Ratio | 0.18% | -5.88% | 26.37% | -22.87% | 17.07% | 27.36% | 5.31% | 3.31% |
| EPS | 0.01 | -0.37 | 1.38 | -1.08 | 0.95 | 1.81 | 0.42 | 0.22 |
| EPS Diluted | 0.01 | -0.37 | 1.31 | -1.08 | 0.92 | 1.75 | 0.41 | 0.22 |
| Weighted Avg Shares Out | 137.31M | 139.01M | 145.66M | 146.57M | 146.05M | 145.43M | 144.23M | 143.97M |
| Weighted Avg Shares Out (Dil) | 141.80M | 139.01M | 154.23M | 146.57M | 151.07M | 150.23M | 149.70M | 148.64M |
Indivior PLC Sued for Securities Law Violations - Contact Levi & Korsinsky Before October 1, 2024 to Discuss Your Rights - INDV
INDV SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Indivior PLC Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 1, 2024 in Indivior PLC Lawsuit - INDV
Investors in Indivior PLC Should Contact The Gross Law Firm Before October 1, 2024 to Discuss Your Rights – INDV
Levi & Korsinsky Reminds Indivior PLC Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 1, 2024 - INDV
The Schall Law Firm Invites Shareholders To Join A Securities Fraud Case Against Indivior PLC
Indivior PLC Sued for Securities Law Violations - Contact Levi & Korsinsky Before October 1, 2024 to Discuss Your Rights - INDV
INDV INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Indivior PLC Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 1, 2024 in Indivior PLC Lawsuit - INDV
Shareholders of Indivior PLC Should Contact Levi & Korsinsky Before October 1, 2024 to Discuss Your Rights – INDV
Source: https://incomestatements.info
Category: Stock Reports